Robert Hindes, MD, has been engaged in clinical research in infectious diseases and virology for almost 3 decades. Starting with clinical, bench, and animal research during his fellowship at Harvard Medical School, Robert Hindes, MD, continued conducting research at Danbury Hospital, Bristol Myers Squibb, Pharmasset, and Gilead. He is currently based in Massachusetts, where he serves as the cofounder and chief medical officer of Trek Therapeutics.
Founded in 2014, Trek Therapeutics is a public benefit corporation that develops treatments for infectious diseases. Recently, the firm completed a Phase 2a randomized, double-blind trial investigating the combination of faldaprevir QD with TD-6450 QD plus ribavirin BID that achieved SVR4 in all subjects with genotype 4 HCV.
HCV, or hepatitis C virus, causes an infection of the liver that often leads to cirrhosis, liver cancer, and liver failure. The condition, which currently affects more than 2.7 million people in the United States, spreads when HCV-infected blood enters the bloodstream of a healthy person. Typically, HCV is spread through sharing needles, medical procedures with unsterilized equipment, and through unprotected sex between men. The virus may also spread during heterosexual sex or when toothbrushes, nail clippers, or razors are shared.